Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (RISE)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Listed as NCT03503318, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 31 times since 2018, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
31 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Apr 2023 [monthly]
Completed PHASE3
▶ Show 26 earlier versions
-
Feb 2022 — Jun 2022 [monthly]
Completed PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Completed PHASE3
-
Sep 2021 — Jan 2022 [monthly]
Completed PHASE3
-
Apr 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Mar 2021 — Apr 2021 [monthly]
Completed PHASE3
-
Feb 2021 — Mar 2021 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .